Initiating Antivirals for the Prevention and Treatment of the Influenza Virus: Highlights of the Latest Safety and Efficacy Data for Pharmacists
On-Demand 0.75-hour Accredited Webcast originally presented at the 11th Annual Directions in Pharmacy® Spring Conference on June 5, 2021.
This activity is supported by an educational grant from
Genentech, a member of the Roche Group.
Genentech, a member of the Roche Group.
Faculty Presenter
Rupal Mansukhani, PharmD, CTTS, FAPhA
Clinical Associate Professor
Rutgers University
Piscataway, New Jersey
Clinical Pharmacist
Morristown Medical Center
Morristown, New Jersey
Moderator
Jessica L. Kerr, PharmD, CDCES
Associate Dean, Office of Professional and Student Affairs
Professor, Department of Pharmacy Practice
Southern Illinois University Edwardsville School of Pharmacy
Edwardsville, Illinois
Program Description
As one of the most common and contagious infectious diseases in the world, influenza results in worldwide outbreaks and epidemics. Not only can influenza outbreaks pose significant economic costs on a society, such as hospitalization and loss of productivity, but also mortality among adults and even healthy children. Influenza is caused by influenza viruses A, B, or C, which lead to acute respiratory symptoms or respiratory failure. It is the role of health-system and community pharmacists to educate patients about treatment options to reduce or prevent symptoms and complications from the virus. Pharmacists can help ensure the safe and effective use of antivirals in pediatric and adult populations for treatment and chemoprophylaxis according to recommendations or guidelines from the CDC, Infectious Diseases Society of America, and the American Academy of Pediatrics. Especially during the COVID-19 pandemic, pharmacists are essential in mitigating the burden of contagious respiratory illnesses, differentiating the clinical presentation of influenza and COVID-19, and addressing patient fears.
Target audience: Community pharmacists
Type of activity: Knowledge
Release date: June 15, 2021
Expiration date: June 15, 2022
Time to complete activity: 0.75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Recognize the patient populations at greatest risk for influenza-related complications
- Recall relevant clinical data supporting the use of antivirals in pediatric populations
- Discuss safety and efficacy data of antivirals in adult populations for prevention and treatment of the influenza virus
- Articulate methods pharmacists can use to improve patient and caregiver education during the influenza season
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-21-250-H01-P. The activity is available for CE credit through June 15, 2022.Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Rupal Mansukhani, PharmD, CTTS, FAPhA, has no financial relationships with commercial interests to disclose.
Moderator
Jessica L. Kerr, PharmD, CDCES, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
